<DOC>
	<DOCNO>NCT01355302</DOCNO>
	<brief_summary>The purpose study determine follow : 1 . Find maximum tolerate dose E7050 give combination cisplatin capecitabine patient advance metastatic solid tumor , 2 ) Whether E7050 combination cisplatin capecitabine effective patient previously untreated gastric cancer versus cisplatin capecitabine alone .</brief_summary>
	<brief_title>E7050 Combination With Cisplatin Capecitabine Versus Cisplatin Capecitabine Alone Patients With Advanced Metastatic Solid Tumors Previously Untreated Gastric Cancer</brief_title>
	<detailed_description>This open-label , multicenter , randomize study consist 2 phase : Phase Ib : safety run-in period 3 ascending dos E7050 combination fix dose Cisplatin Capecitabine . This phase enroll approximately 10 15 patient . - Phase II : randomize 2-arm design enroll 80 patient . In phase II portion , Patients receive study treatment , E7050 combination Cisplatin Capecitabine versus Cisplatin Capecitabine Alone ) approximately six 21-day cycle ( 18 week ) . Beyond 18 week , patient experience clinical benefit may continue E7050 , without Capecitabine ( Arm 1 ) , may continue Capecitabine alone ( Arm 2 ) , depend original randomization treatment arm . Patients continue treatment long clinical benefit sustain treatment well tolerate , occurrence progressive disease ( PD ) , unacceptable toxicity , withdrawal consent , withdrawal investigator , whichever occur first . Patients participate either phase Ib phase II .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Inclusion Criteria Histologically confirm , unresectable , locally advanced metastatic gastric cancer , include adenocarcinoma gastroesophageal junction ( Phase II ) . For Phase Ib portion , unresectable , locally advanced metastatic solid tumor ; ECOG PS 01 ; Blood pressure must wellcontrolled . Patients must history hypertensive crisis hypertensive encephalopathy ; Adequate end organ function Exclusion Criteria Gastric cancer patient complete gastrectomy ; Patients know HER2 overexpressing advanced metastatic gastric cancer ; Previously receive E7050 , chemical derivative , anticMet , antiangiogenic therapy , ( prior antiangiogenic therapy permit Phase Ib ) . For Phase Ib prior systemic therapy allow long PS end organ function meet entry criterion ; For Phase II prior palliative chemotherapy permit . Adjuvant/neoadjuvant chemotherapy permit less 12 month elapse end adjuvant/neoadjuvant therapy first recurrence ; Known central nervous system lesion , except asymptomatic nonprogressing , treat brain metastasis . Treatment brain mets , complete least 4 week prior Day 1 Palliative radiotherapy permit throughout study period . Prior palliative radiotherapy within 30 day prior commence study treatment ; Clinically significant hemoptysis ; Patients know dihydropyrimidine dehydrogenase deficiency ; Patients clinically significant hearing loss may diminish treatment cisplatin plus capecitabine ( significance hearing loss determine Investigator ; Serious nonhealing wound , ulcer , active bone fracture ; Major surgical procedure , open biopsy , significant traumatic injury within 21 day prior commence study treatment ; Clinically significant gastrointestinal bleeding within 6 month prior first dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Gastric</keyword>
	<keyword>Phase I</keyword>
	<keyword>Phase II</keyword>
</DOC>